NeurologyLive® Friday 5 — January 13, 2023

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Understanding the Widespread Impacts of The Ohio State University Wexner Medical Center’s Teleneurology Program

In a Gold Standard Centers NeurologyLive® feature, we explore the virtual care program built by The Ohio State University Wexner Medical Center to learn more about how it allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

Understanding the Widespread Impacts of The Ohio State University Wexner Medical Center’s Teleneurology Program

2: Peer Exchange: Use of ATN Classification for Alzheimer’s Disease in Clinical Practices

IN episode 7 of this Peer Exchange, the panel of experts in dementia discusses ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer disease. The NeurologyLive® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.

Use of ATN Classification for Alzheimer’s Disease in Clinical Practices

3: NeuroVoices: RJ Tesi, MD, on XPro1595 and the Role of TNF Inhibitors in the Alzheimer Field

In the latest edition of our in-depth Q&A series, the president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

NeuroVoices: RJ Tesi, MD, on XPro1595 and the Role of TNF Inhibitors in the Alzheimer Field

4: Special Episode: Lecanemab Approved for Alzheimer Disease

In a special episode of a podcast from NeurologyLive®'s Mind Moments®, brings you an exclusive interview with Sharon Cohen, MD, FRCPC, a behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. [LISTEN TIME: 14 minutes]

Special Episode: Lecanemab Approved for Alzheimer Disease

5: Functionality of Robotic Exoscope to Improve Neurosurgery: Richard Williamson, MD, FAANS

The neurosurgeon at Allegheny Health Network provided background on a new, state-of-the-art tool designed to ultimately improve neurosurgical procedures, insight on how it differs from other robotic technology, and whether it can be easily applicable to surgery rooms across the country. [WATCH TIME: 3 minutes]

Functionality of Robotic Exoscope to Improve Neurosurgery: Richard Williamson, MD, FAANS

—————————————————

Nominations for Giants of Multiple Sclerosis® are open! This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in multiple sclerosis. Nominations close on January 31, 2023!

Nominate: neurologylive.com/Giants-of-MS

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.